Citius Pharmaceuticals (CTXR) Other financing activities (2014 - 2025)
Citius Pharmaceuticals' (CTXR) quarterly Other financing activities came in at $3.5 million in Q1 2025, up 34.64% on a QoQ basis from $2.6 million in Q4 2024.
Citius Pharmaceuticals (CTXR) Other financing activities (2014 - 2025) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 11 years of Other financing activities data on file, last reported at $3.5 million in Q1 2025.
- Quarterly Other financing activities changed N/A year-over-year to $3.5 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $19.9 million (changed N/A YoY) and the FY2024 annual result came in at $13.8 million, changed 0.04% from the prior year.
- Other financing activities climbed to $3.5 million in Q1 2025, from $2.6 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $18.4 million in Q3 2021 to a low of -$70.9 million in Q2 2021.
- A 4-year average of -$5.4 million and a median of $3.0 million in 2024 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 6472.85% in 2021, down 8441.21% in 2021.
- Tracing CTXR's Other financing activities over 4 years: stood at $18.4 million in 2021, then declined by 25.05% to $13.8 million in 2023, then sank by 81.3% to $2.6 million in 2024, then surged by 34.64% to $3.5 million in 2025.
- The last three Other financing activities figures came in at $3.5 million (Q1 2025), $2.6 million (Q4 2024), and $84733.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Citius Pharmaceuticals | 15.60 Mn | 15.60 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 3.47 Mn |
| Mar 31, 2025 | 3.47 Mn |
| Dec 31, 2024 | 2.57 Mn |
| Dec 31, 2024 | 2.57 Mn |
| Sep 30, 2024 | 84,733.00 |
| Sep 30, 2024 | 84,733.00 |
| Sep 30, 2023 | 13.77 Mn |
| Sep 30, 2023 | 13.77 Mn |
| Sep 30, 2021 | 18.37 Mn |
| Sep 30, 2021 | 18.37 Mn |
| Jun 30, 2021 | -70.90 Mn |
| Jun 30, 2021 | -70.90 Mn |
| Sep 30, 2020 | 279,449.00 |
| Sep 30, 2020 | 279,449.00 |
| Jun 30, 2020 | 849,963.00 |
| Jun 30, 2020 | 849,963.00 |
| Mar 31, 2020 | 6.03 Mn |
| Mar 31, 2020 | 6.03 Mn |
| Dec 31, 2019 | 106.00 |
| Dec 31, 2019 | 106.00 |